Experiences of working as a clinical nurse while pregnant during the coronavirus disease-2019 pandemic: a qualitative study DOI Creative Commons
Lin Wu,

Wing Fai Yeung,

Yao Pei

et al.

BMC Nursing, Journal Year: 2025, Volume and Issue: 24(1)

Published: Feb. 3, 2025

Abstract Background Working as a pregnant clinical nurse might experience range of challenges, such significant anatomical and physiological changes well emotional cognitive changes. That be particularly obvious under the historical background coronavirus disease-2019 (COVID-19) pandemic. However, dearth studies has explored experiences working during this special period. This study aimed to explore while COVID-19 Methods A descriptive qualitative design was selected. Purposive sampling, combined with maximum variation strategy snowball were utilized identify select participants from tertiary-teaching hospitals, specialized community hospitals in Zhejiang Province, southeastern China. Online semi-structured individual interviews used collect data, conventional content analysis analyze data. Results Eleven Chinese nurses mean age 31.8 years, ranging 26 40 participated study. Four themes twelve subthemes emerged: (1) still adhering work despite being pandemic; (2) pregnancy pandemic is an ordinary nurse; (3) staying life phase mother; (4) growth gains mother. Conclusion The suffered various difficulties Managers, occupational health other system leaders, policymakers should aware importance establishing environment that guarantees safe continued pregnancy. Future focus on establishment specific guidelines manuals regarding how worked, development self-protection interventions Moreover, research moral stigma bullying nursing deserves further exploration. Clinical trial number Not applicable.

Language: Английский

Therapeutic strategies for COVID-19: progress and lessons learned DOI Open Access
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley

et al.

Nature Reviews Drug Discovery, Journal Year: 2023, Volume and Issue: 22(6), P. 449 - 475

Published: April 19, 2023

Language: Английский

Citations

411
REVIEW OF LABORATORY DIAGNOSTICS EVOLUTION IN NIGERIA'S RESPONSE TO COVID-19 DOI Creative Commons

Chinedu Paschal Maduka,

Adebukola Adejumoke Adegoke,

Chiamaka Chinaemelum Okongwu

et al.

International Medical Science Research Journal, Journal Year: 2023, Volume and Issue: 3(1), P. 1 - 23

Published: Oct. 16, 2023

This comprehensive review elucidates the evolution of laboratory diagnostics in Nigeria's response to COVID-19, emphasizing its pivotal role managing infectious diseases. The purpose this is analyze advancements diagnostic approaches and their implications on effective pandemic management future preparedness. A robust research strategy was employed, involving a systematic synthesis critical peer-reviewed articles, focusing innovations, developments, challenges procedures during pandemic. results revealed significant progress methodologies technologies, with enhanced capabilities detect control spread diseases, despite logistical, infrastructural, regulatory challenges. concluded that have multifaceted impacts shaping strategies altering public health policy practice. Recommendations include strengthening capacities, developing sustainable strategies, investing development, promoting international collaboration, enhancing systems. insights derived are instrumental envisioning evolving driving transformative changes healthcare delivery, ensuring more approach disease management. Keywords: Laboratory Diagnostics, Infectious Diseases, Pandemic Management, Diagnostic Advancements, Public Health Policy, Healthcare Systems.

Language: Английский

Citations

66
ICU-acquired infections in immunocompromised patients DOI
Louis Kreitmann, Julie Helms, Ignacio Martín‐Loeches

et al.

Intensive Care Medicine, Journal Year: 2024, Volume and Issue: 50(3), P. 332 - 349

Published: Jan. 10, 2024

Language: Английский

Citations

32
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir DOI Creative Commons
Karolina Akinosoglou, Georgios Schinas,

Charalambos Gogos

et al.

Viruses, Journal Year: 2022, Volume and Issue: 14(11), P. 2540 - 2540

Published: Nov. 17, 2022

Despite the rapid development of efficient and safe vaccines against COVID-19, need to confine pandemic treat infected individuals on an outpatient basis has led approval oral antiviral agents. Taking into account viral kinetic pattern SARS-CoV-2, it is high importance intervene at early stages disease. A protease inhibitor called nirmatrelvir coupled with ritonavir (NMV/r), which acts as a CYP3A inhibitor, delivered formulation, shown much promise in preventing disease progression high-risk patients no for supplemental oxygen administration. Real-world data seem confirm drug combination’s efficacy safety all variants concern adult populations. Although, not fully clarified, rebound recurrence COVID-19 symptoms have been described following treatment; however, more potential resistance issues concerning Mpro gene, drug’s therapeutic target, are needed. NMV/r gamechanger fight by hospitalizations halting severity; therefore, research future greater awareness its use warranted.

Language: Английский

Citations

55
Evolution and Control of COVID-19 Epidemic in Hong Kong DOI Creative Commons
Shuk‐Ching Wong, Albert Ka-Wing Au,

Janice Lo

et al.

Viruses, Journal Year: 2022, Volume and Issue: 14(11), P. 2519 - 2519

Published: Nov. 14, 2022

Hong Kong SAR has adopted universal masking, social distancing, testing of all symptomatic and high-risk groups for isolation confirmed cases in healthcare facilities, quarantine contacts as epidemiological control measures without city lockdown or border closure. These successfully suppressed the community transmission pre-Omicron SARS-CoV-2 variants lineages during first to fourth wave. No nosocomial infection was documented among workers 300 days. The strategy COVID-19 containment provide additional time achieve population immunity by vaccination. near-zero situation about 8 months 2021 did not enable adequate immunization eligible population. A combination factors identified, especially complacency associated with low local activity, together vaccine hesitancy. importation highly transmissible Omicron variant kickstarted fifth wave COVID-19, which could no longer be controlled our initial measures. explosive wave, partially contributed vertical airborne high-rise residential buildings, resulted over one million infection. In this review, we summarize epidemiology public health against dissemination until day 1000.

Language: Английский

Citations

51
Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials DOI Creative Commons
Adam C. Levine, Yuriko Fukuta, Moisés A. Huamán

et al.

Clinical Infectious Diseases, Journal Year: 2023, Volume and Issue: 76(12), P. 2077 - 2086

Published: Feb. 16, 2023

Outpatient monoclonal antibodies are no longer effective and antiviral treatments for coronavirus disease 2019 (COVID-19) remain largely unavailable in many countries worldwide. Although treatment with COVID-19 convalescent plasma (CCP) is promising, clinical trials among outpatients have shown mixed results. We conducted an individual participant data meta-analysis from outpatient to assess the overall risk reduction all-cause hospitalizations by day 28 transfused participants. Relevant were identified searching Medline, Embase, medRxiv, World Health Organization Research Database, Cochrane Library, Web of Science January 2020 September 2022. Five included studies 4 enrolled 2620 adult patients. Comorbidities present 1795 (69%). The virus neutralizing antibody dilutional titer levels ranged 8 14 580 diverse assays. One hundred sixty 1315 (12.2%) control patients hospitalized, versus 111 1305 (8.5%) CCP-treated patients, yielding a 3.7% (95% confidence interval [CI], 1.3%-6.0%; P = .001) absolute 30.1% relative hospitalization. hospitalization was greatest those both early transfusion high 7.6% CI, 4.0%-11.1%; .0001) accompanied at 51.4% reduction. No significant seen >5 days after symptom onset or receiving CCP titers below median titer. Among COVID-19, reduced rate may be most when given within 5 higher.

Language: Английский

Citations

40
Clinical course and management of COVID-19 in the era of widespread population immunity DOI
Eric A. Meyerowitz, Jake Scott, Aaron Richterman

et al.

Nature Reviews Microbiology, Journal Year: 2023, Volume and Issue: 22(2), P. 75 - 88

Published: Dec. 19, 2023

Language: Английский

Citations

36
Remdesivir for the Treatment of COVID-19: A Narrative Review DOI Creative Commons
Patrick O. Godwin, Bryan Polsonetti,

Michael F. Caron

et al.

Infectious Diseases and Therapy, Journal Year: 2024, Volume and Issue: 13(1), P. 1 - 19

Published: Jan. 1, 2024

Despite the wide availability of effective vaccines, COVID-19 continues to be an infectious disease global importance. Remdesivir is a broad-spectrum antiviral and was first US Food Drug Administration-approved treatment for COVID-19. In clinical guidelines, remdesivir currently only recommended use in hospitalized patients with COVID-19, or without supplemental oxygen requirement. It also nonhospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who are at high risk progression disease. This narrative review explores evidence across various outcomes evolution guidelines through survey over time randomized controlled trials, observational studies, meta-analyses. Remdesivir, compared standard care, appears improve survival variety patient populations spectrum severity SARS-CoV-2 variant periods. recovery, increase rate reduce on readmission rates. More recent large, real-world studies further support early range populations, including those immunocompromising conditions. When people get sick which caused by virus, may needed prevent serious illness. Studies have found that treating can save lives keep from getting sicker. help better faster, need less time, avoid having go back hospital. Newer treated settings, outside research environments, show likely many different groups patients, health conditions weaken their body's ability fight infection. Because this research, recommend should given some hospital stay other reasons but condition puts them

Language: Английский

Citations

12
The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis DOI

Gangqiang Sun,

Ke Lin, Jingwen Ai

et al.

Clinical Microbiology and Infection, Journal Year: 2024, Volume and Issue: 30(12), P. 1505 - 1513

Published: July 14, 2024

Language: Английский

Citations

9
Tracing Emergence of SARS-CoV-2 Variants: Insights from Comprehensive Assessment Using Reverse Transcription Polymerase Chain Reaction and Whole Genome Sequencing DOI Creative Commons

D. Na,

Yuna Hong, C. Lee

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(2), P. 311 - 311

Published: Jan. 31, 2025

The emergence and evolution of SARS-CoV-2 variants, such as Delta Omicron, pose significant challenges to pandemic management. This study evaluated the effectiveness reverse-transcription polymerase chain reaction (RT-PCR) whole-genome sequencing (WGS) in detecting characterizing variants using 624 samples collected South Korea from mid-2021 mid-2022. Two RT-PCR genotyping assays demonstrated a high concordance rate (90.4%) identifying variant during its dominance. In contrast, WGS revealed extensive genetic diversity among Omicron sub-lineages, 29 distinct including two Korea-specific (BA.1.1.5 BA.2.3.8). Clustering analysis data highlighted groupings BA.1, BA.2, BA.5 with overlap shared mutations suggesting evolutionary convergence. Sub-lineage expanded rapid transmission phases subsequently consolidated dominant lineages emerged. These findings highlight complementary strengths underscore importance integrating these methodologies for effective monitoring public health response.

Language: Английский

Citations

1